RHOA and neoplasm: In group II, the RhoA-modulators CCG-1423, narciclasine, the pan-Rac inhibitor EHT-1864 as well as the adenylate-cyclase inhibitor KH7 mainly resulted in cytotoxic effects, which in turn are likely to impair tumor cell invasion.